NCT06615050 is a Phase 3 clinical trial of Tacrolimus (Tac) in Graft-versus-host Disease (GVHD), sponsored by Incyte Corporation.

Who is sponsoring NCT06615050?

NCT06615050 is sponsored by Incyte Corporation.

What drugs are being tested in NCT06615050?

Interventions in NCT06615050: Tacrolimus (Tac), Methotrexate (MTX), Ruxolitinib (Rux), Cyclophosphamide, Mycophenolate mofetil (MMF).

What condition does NCT06615050 study?

NCT06615050 studies Graft-versus-host Disease (GVHD).

Is NCT06615050 still recruiting?

NCT06615050 is currently recruiting now. Last updated 16 April 2026.

Last reviewed 2026-04-16 · How we verify

NCT06615050

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)

Recruiting now Phase 3 Last updated 16 April 2026

What this trial tests

Phase 3 trial testing Tacrolimus (Tac) in Graft-versus-host Disease (GVHD) in 572 participants. Currently enrolling.

Timeline

2 April 2025

Primary endpoint
17 January 2031

17 January 2031

Quick facts

Lead sponsor	Incyte Corporation
Phase	Phase 3
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	572
Start date	2 April 2025
Primary completion	17 January 2031
Estimated completion	17 January 2031
Sites	30 locations across United States

Drugs / interventions tested

Tacrolimus (Tac)
Methotrexate (MTX) — full drug profile →
Ruxolitinib (Rux) — full drug profile →
Cyclophosphamide (cyclophosphamide) — full drug profile →
Mycophenolate mofetil (MMF) — full drug profile →

Conditions studied

Graft-versus-host Disease (GVHD) — all drugs for Graft-versus-host Disease (GVHD) →

Sponsor

Incyte Corporation — full company profile →

Who can join

18 and older, any sex, with Graft-versus-host Disease (GVHD). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to assess Tacrolimus/Methotrexate/Ruxolitinib versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

New age GVHD prophylaxis regimens: what works for what donor and why.
Gooptu M, Koreth J. · · 2025 · PMID 41348045 · DOI 10.1182/hematology.2025000737

Verify or expand the search:

Other trials of Tacrolimus (Tac)

Trials testing the same drug.

NCT03674411 — Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy · Phase 2 · active not recruiting
NCT02217410 — CCFZ533X2201 - PoC Study in de Novo Renal Transplantation · Phase 1, PHASE2 · completed

Other recruiting trials for Graft-versus-host Disease (GVHD)

Currently open trials in the same condition.

NCT06626737 — Dapagliflozin in Allo-HCT for aGVHD · Phase 2 · recruiting

Other Incyte Corporation trials

Trials by the same sponsor.

NCT07124078 — A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Di · Phase 2 · recruiting
NCT07441694 — Study of INCA036978 in Participants With Myeloproliferative Neoplasms · Phase 1 · recruiting
NCT07522073 — A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancre · Phase 3 · recruiting
NCT07448155 — A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of INCA033989 Following Subcutaneous or Intravenous A · Phase 1 · active not recruiting
NCT07284849 — A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 i · Phase 3 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06615050 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Incyte Corporation
Last refreshed: 16 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06615050.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing